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Objective: To identify and characterize treatment compliance profiles of glaucoma patients 
and evaluate the association with intraocular pressure (IOP).
Methods: A computerized device (Travalert®) that recorded daily instillation times and eye-drop 
counts was given for 3 months. Patients were declared compliant when at least 2 drops were 
instilled per day. Compliance rates were calculated for weekdays and weekends, separately, over 
8 consecutive weeks. A principal components analysis (PCA) was followed by an ascendant 
hierarchical classification (AHC) to identify compliance groups.
Results: 140 patients were recruited (mean age 65.5 years; 51.8% female) of whom 83.6% 
had primary open-angle glaucoma with mean IOP 23.9 mmHg before Travalert® use. 60.7% 
were treated with DuoTrav® (travoprost timolol fixed combination) and 39.3% with   travoprost. 
The PCA identified two axes (compliance and treatment weeks). The AHC identified 
3   compliance groups: ‘high’ (56.6%, approx. 80% compliance), ‘medium’ (21.2%, approx. 
50% compliance), and ‘low’ (22.1%, approx. 20% compliance). Demographics and glaucoma 
parameters did not predict low compliance. Final mean IOP was 16.1 mmHg, but higher in the 
low compliance group (17.7 mmHg, P = 0.02).
Conclusions: Compliance measurement by a medical device showed compliance rates ,80% 
by 50% (approx.) of patients, significantly impacting IOP control. No demographic or glaucoma 
variable was associated with low compliance.
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Introduction
Glaucoma occurs in about 2% of the population aged more than 40 years.1–7 It is esti-
mated that glaucoma affects more than 500,000 people in England and Wales alone, 
and more than 70 million worldwide.8
Topical treatments have been reported to delay onset and the worsening of 
glaucoma,9 but they must be instilled for life or until a curative treatment becomes 
available. When the intraocular pressure (IOP) is poorly controlled, sufferers may 
eventually notice a severe restriction of visual fields or even a loss of central vision.10 
Though blindness from glaucoma is uncommon, it is responsible wholly or in part for 
13% of patients on the blind register in England and Wales.11
It is also reported that patients with chronic medical conditions self-administer only 
30%–70% of their prescribed medication, and about 50% discontinue treatment in the 
initial months of therapy.12 Glaucoma is no exception, as reported by similar (50%) 
rates of treatment compliance published in the ophthalmic literature.13–21Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Friedman et al13 analyzed pharmacy claims data and 
patients’ clinical files and calculated a ‘medication possession 
ratio’ (MPR) to estimate adherence with topical glaucoma 
therapy. The ratio expressed the number of days when a 
patient possessed eye-drops as a proportion of the observa-
tion period. They reported mean MPR values from 0.63 to 
0.68 that were independent of the visual field mean deviation. 
Within 6 months, half of all new patients had discontinued 
therapy. A French study analyzed self-declared treatment 
compliance and found that 68% of patients stated they were 
fully compliant, 16% did not follow the administration 
  schedule, and only 6% admitted they had forgotten instil-
lations on certain days. The principal reasons given for 
compliance failure were forgetfulness, time constraints, or 
a poor doctor relationship.17,22
Glaucoma surgery is, at least for some patients, a way 
to avoid compliance issues. Breusegem et al23 found that 
patients having had trabeculectomy added with topical 
ketorolac or fluorometholone had a significantly reduced need 
for additional postoperative IOP-lowering medication. Tube 
implant during glaucoma surgery24,25 has shown promising 
results requiring confirmatory results.
The effect of deficient compliance on IOP control 
and visual impairment has been reported by 2 authors. 
  Konstas et al26 found that noncompliant patients, determined 
by 2 independent observers using a formal questionnaire, 
had higher IOP values (22.9 versus 18.5 mmHg) and more 
severe visual field loss (10.8 versus 7.0 dB, mean defect). 
Forsman et al,27 applying a retrospective analysis, described 
associations between the incidence of blindness and poor 
treatment compliance.
Various methods are used to measure treatment compli-
ance, eg, patient questionnaires, physicians’ reports, and 
pharmacy claims data, with high possible bias on the rel-
evance of the findings. However, more objective methods 
exist, such as Travalert® (Alcon Inc, Fort Worth, Texas, 
USA), an electronic device that accomplishes several objec-
tives aimed at improving treatment adherence.28 The device 
reminds patients when to instill their glaucoma medication 
and gives physicians objective compliance data for treatment 
decisions. The dosing aid monitors compliance electronically 
and makes it possible to track a patient’s dosing history. Other 
devices exist to help patients by reminding them.29
Travalert® (Alcon, Inc., Fort Worth, TX, USA) is a 
computerized bottle holder30 that reminds patients to instill 
their drops, assists with administering drops, and records 
dosing times. It is used with travoprost (Travatan®, Alcon 
Inc, Fort Worth, Texas, USA) and the travoprost/timolol fixed 
  combination (Duotrav®, Alcon Inc, Fort Worth, Texas, USA). 
The ophthalmologist programs the number and timing of 
instillations before giving Travalert® to the patient and recov-
ers accurate dosing data at the patient’s next visit. During 
each control visit, Travalert® is connected to the ophthalmolo-
gist’s computer, and all instillation dates and times are listed. 
The number of instillations properly performed (correct time 
and quantity) are expressed as a compliance rate.
The aims of our study were (1) to assess the convenience 
of using Travalert®, (2) to measure patient compliance with 
Travalert®, (3) to evaluate associations between compliance 
and IOP control, and (4) to identify risk factors of poor 
compliance.
Materials and methods
The present survey was conducted according to French law. 
The protocol was reviewed and approved by the Comité 
consultatif sur le traitement de l’information en matière de 
recherche dans le domaine de la santé and the Commission 
nationale informatique et liberté.31–33
Selected ophthalmologists were those specialized in glau-
coma treatment. Centers were required to keep accurate and 
accessible patient records and be able to devote the necessary 
resources prior to participating in this survey. The study was 
an ‘open label’ design in patients with glaucoma or ocular 
hypertension (OHT) who, after consenting, were required 
to meet the inclusion/exclusion criteria. Patients visited 
their ophthalmologist 2 times: when prescribing Travalert® 
and at the next control visit where compliance data were 
collected (ie, the interval between visits was not fixed by 
the protocol).
As this was an observational survey, the protocol did not 
specify how ophthalmologists should inform their patients, 
apart from telling them how to use Travalert®. Lastly, 
how doctors discussed the results with patients was not 
  standardized. At the time of this study Travalert® was EC 
labeled and available to ophthalmologists and patients. 
  Prescription drugs were reimbursed by the French sick funds, 
and physicians’ fees for time spent completing the study case 
report forms was approved by the Conseil National de l’Ordre 
des Médecins.
Patients were required to meet the following inclusion 
  criteria: (1) a diagnosis of primary open-angle glaucoma (POAG) 
or treated OHT, (2) age 18 years or above, (3) Travalert® used 
for at least 4 weeks, (4) ability to read and understand French, 
(5) received information on the study’s purpose and gave 
consent prior to the study, and (6) medical records accessible 
and properly documented.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Conversely, patients with the following characteristics 
were excluded from the survey: (1) age below 18 years, 
(2) secondary glaucoma (congenital, inflammatory, neo-
vascular, or following cataract surgery), (3) closed-angle 
glaucoma, (4) participation in a concomitant clinical trial 
or observational survey, (5) severe co-morbidities directly 
affecting compliance (eg, severe depression), (6) severe dry-
eye (.5 instillations per day), (7) numerous non-glaucoma 
treatments judged by the ophthalmologist as likely to impact 
indirectly on glaucoma drug compliance, (8) medical records 
lacking relevant retrospective data, or (9) refusal to partici-
pate. To be close to usual practice, there was no exclusion 
criteria related to lack of efficacy and or local tolerance (eg, 
hyperemia).
The following information was collected: inclusion and 
exclusion findings, socio-demography, POAG/OHT his-
tory, current treatment, IOP and visual acuity (measured at 
diagnosis, and both before and after Travalert®). Data were 
transcribed from the patients’ records to the case report forms 
by the ophthalmologists.
The utility of Travalert® in glaucoma management was 
assessed by an 8 item, 6-point rating scale scored from ‘1’ 
(no help at all) to ‘6’ (very positive help) that assessed the 
following dimensions: (1) instillation help, (2) time reminder, 
(3) use of the instillation listing, (4) compliance index, 
(5) clinical interpretation, (6) discussion with the patient, 
(7) treatment decision, and (8) global evaluation (average 
of previous dimensions). These questions were formulated 
with glaucoma experts during a focus group meeting. The 
objective was to capture the information they would need 
before incorporating compliance measurements into their 
treatment decisions. The questions were answered by investi-
gators. Case report forms were not anonymized so to enable 
patient-based quality control.
The statistical analysis was conducted with SAS, release 
9.2 (SAS Institute, NC, USA). The average delay between 
the two visits yielded daily compliance data over an 8-week 
period. A patient was declared compliant on any given day 
when at least 2 drops (one in each eye) were instilled. The 
diurnal instillation pattern (morning or evening) was not 
taken into account. The compliance rate of each patient 
was calculated for the entire 8 weeks and for weekdays and 
weekends separately. We used an automatic classification 
algorithm to identify compliance groups that did not specify 
the number of groups, in preference to pre-defined rules based 
on prior knowledge. The reasons for the decision were as 
follows: (1) complexity of the daily compliance informa-
tion structure, (2) scarcity of available prior information on 
compliant patients, and (3) need for homogenous patient 
groups (in terms of compliance profiles) to enhance the likeli-
hood of detecting IOP differences. A principal components 
analysis (PCA)34 was followed by an ascendant hierarchical 
classification (AHC)35 to identify compliance groups. With 
this type of analysis, the number of groups is not identified a 
priori. A distance is computed between each patient, and the 
number of the group is identified according to a dendrogram. 
The algorithm minimizes within group variance and maxi-
mizes between group variance. Characteristics of compliance 
groups were compared using Chi-squared tests or ANOVA. 
All statistical tests were 2-sided with alpha fixed at 5%.
Results
The study population was comprised of 140 patients recruited 
by 17 physicians. Travalert® documentation was completed for 
113 patients (80.7%), the main reason of not participating to 
the analysis being less than 8 weeks of compliance measure-
ments. No major selection bias was observed for this subgroup, 
which was similar to the original population in terms of socio-
demographics and clinical factors (POAG versus OHT, IOP, 
and co-morbidities). This manuscript reports findings in the 
population with documented compliance (n = 113).
Sexes of eligible patients were balanced (females 51.8%), 
and the mean age was 65.5 ± 12.1 years. Most patients 
(64.0%) were retired and did not live alone (77.0%). The 
frequency of POAG (83.6%) was higher than ocular hyper-
tension. Most patients were prescribed the travoprost/timolol 
combination Duotrav® (60.7%). The remainder received 
travoprost (39.3%), and treatments were generally used alone 
(77.1%). More females (70.8%) were treated with Duotrav® 
than males (50.7%, P = 0.015) and patients with POAG were 
more frequently prescribed the combination (P , 0.05). 
Mean time since glaucoma onset was 4.7 ± 5.5 years, but it 
was longer for patients treated with Duotrav® (5.6 ± 5.9 years) 
than for travoprost (3.6 ± 4.7 years, P = 0.06) although 
statistically not significant. At inclusion, 56.4% of patients 
exhibited at least one non-ocular comorbidity and 31.4% 
had at least one ocular comorbidity, the most frequent being 
unoperated cataract (14.3%) or retinal detachment (4.3%). 
Glaucoma treatment was mainly pharmacological prior to the 
use of Travalert®, with only 17.9% of patients receiving sur-
gery and 10.0% having laser therapy. Lastly, no differences 
were found between the 3 groups of compliance on general 
co-morbidities (cardiovascular diseases, dementia, hepatic 
disease, renal disease, cancer, chronic pulmonary disease, 
autoimmune disease, neurologic disease, gastrointestinal 
disease, metabolic diseases, other diseases) (Table 1).Clinical Ophthalmology 2010:4
Table 1 socio-demographics and medical parameters according to compliance group
Low 
n = 25
Medium 
n = 24
High 
n = 64
P- 
valuea
gender: 
  Male 
  Female
 
16 (64.0%) 
9 (36.0%)
 
13 (54.2%) 
11 (15.8%)
 
29 (46.0%) 
35 (54.0%)
 
0.30
Age 67.4 (14.8) 68.8 (8.8) 65.3 (11.9) 0.44
POAg 19 (76.0%) 22 (91.7%) 57 (89.1%) 0.22
Normal pressure glaucoma 3 (12.0%) 1 (4.2%) 1 (1.6%) 0.07
retinal detachment 2 (8.0%) 1 (4.2%) 3 (4.7%) 0.85
Not operated cataract 3 (12.0%) 2 (8.3%) 12 (18.8%) 0.49
Diabetic retinopathy 1 (4.0%) 1 (4.2%) 0 (0%) 0.19
Uveitis 0 (0%) 1 (4.2%) 0 (0%) 0.21
iOP at diagnosis (mmhg) 25.0 (6.1) 23.6 (4.2) 24.0 (6.3) 0.73
Time since glaucoma diagnosis (years) 4.0 (7.4) 3.6 (3.4) 5.4 (5.8) 0.47
Previous surgery 6 (24.0%) 3 (12.5%) 12 (18.8%) 0.61
Previous laser 3 (12.0%) 3 (12.5%) 6 (9.4%) 0.77
Monotherapy treatment 18 (72.0%) 21 (87.5%) 46 (71.9%) 0.32
Note: aComparison of the 3 compliance groups.
Abbreviations: POAg, primary open-angle glaucoma; iOP, intraocular pressure.
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Figure 1 Average compliance rates over the study period (iC 95%). N = 113 at all 
time points.
Compliance data were recovered from the Travalert® 
device, which recorded each instillation including times 
and number of drops. When entire weeks were combined, 
mean compliance was 60.0% (±25.9%) with little difference 
between weekdays (58.9%) and weekends (60.4%). Also, 
compliance was virtually stable over time, apart from the 
first week where it fluctuated from 60.3% to 63.6% during 
weekdays, and from 56.7% to 63.3% during the weekend 
(Figure 1).
Compliance information was explored by the PCA and 
yielded 2 main axes. The first axis explained 53% of the 
variance and the second 9%. Eigen values of other axes 
(measuring axis variance contributing to total variance) 
reached less than unity and were ignored (ie, their inclusion 
did not add information). Figure 2b depicts the resulting 
factorial structure. Axis 1 depicts compliance findings and 
shows better compliance in later treatment weeks. Axis 2 
depicts temporal findings and shows lower compliance in 
earlier weeks. Figure 2a plots individual patients within 
the factorial structure plan, according to the 3 compliance 
groups identified by the subsequent AHC analysis, and shows 
that the groups were ordered consistently along Axis 1. 
When all 8 weeks were merged, treatment compliance days 
amounted to 22.1% for the low compliance group, 51.1% 
for the medium compliance group, and 78.1% for the high 
compliance group.
Percent compliance identified by Travalert® during 8 weeks 
of treatment is shown in Figure 3 according to compliance 
group. The low compliance group featured 2   characteristics: 
(1) decreasing compliance during the first two weeks, and 
(2) very low compliance on weekends.
Table 2 shows mean maximum IOP values measured at 
the final visit for the compliance groups in Figure 2b, and 
shows no statistically significant IOP difference between 
the 3 groups. However, on comparing the low compliance 
group with the combined medium and high compliance 
groups, maximum IOP values were higher in low compli-
ance patients (P = 0.02). This difference persisted after 
adjusting for IOP at diagnosis.
Figure 4 depicts mean IOP values in the worst affected 
eye at diagnosis, at Travelert® initiation, and on the last 
study visit for the 3 compliance groups. After 8 weeks of 
treatment, worst-eye IOP values were higher (P = 0.04) in 
the low compliance group.
The utility of Travalert® for various aspects of glaucoma 
management was evaluated by the physicians (rating: 1 ‘none’ 
to 6 ‘high’) and analyzed for the 3 compliance groups 
(Figure 5). Physicians’ ratings of Travalert® differed between Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 2 Principal component analysis results. A) Principal component analysis patients plotted after hCA. B) Principal component analysis factorial structure.
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Figure 3 Percent compliance rates over 8 weeks of treatment, during weekdays and weekends, according to compliance group. N = 113 at all time points.
Patients (n = 27) providing insufficient data for clustering 
into any of the 3 compliance groups received scores close to 
the low compliance group, or even lower.
Discussion
The objectives of this study were to identify patient 
  compliance profiles, risk factors for poor compliance, and 
consequences of poor compliance on IOP control. To do 
compliance groups. For example, the high compliance group 
was given a higher ‘global evaluation’ score than the other 
groups, accompanied by significantly higher scores for the 
‘instillation help’, ‘time reminder’, and ‘compliance index’ 
dimensions. In other respects, ‘instillation listing’ and ‘com-
pliance interpretation’ scores were similar for low and high 
compliance groups and significantly higher than that for the 
medium compliance group.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
736
Nordmann et al
IOP – worst eye
25.00
19.92
17.68
23.59
23.98
15.75
18.79
15.62
18.54
15
17.5
20
22.5
25
27.5
IOP at diagnosis IOP at the last visit
m
m
 
H
g Low compliance
Medium compliance
High compliance
P = 0.72
P = 0.45
P = 0.07
initiation
IOP at Travalert
Figure 4 Mean iOP values in the worst affected eye at salient visits.
Table 2 Maximum iOP of each compliance group at the last visit
Cluster 1: Low 
compliance 
n = 25
Cluster 2: Medium 
compliance 
n = 24
Cluster 3: High 
compliance 
n = 64
P-value
Max iOP (mmhg) 
  Mean (sd) 
  Median (Min–Max)
 
17.7 (5.3) 
17.0 (12–40)
 
15.8 (3.3) 
15.0 (10–24)
 
15.6 (3.3) 
16.0 (9–25)
 
0.069
Cluster 1: Low  
compliance n = 25
Clusters 2 and 3: Medium and high  
compliance n = 88
Max iOP (mmhg) 
  Mean (sd) 
  Median (Min–Max)
 
17.7 (5.3) 
17.0 (12–40)
 
15.7 (3.3) 
15.0 (9–25)
 
0.021
Note: Max iOP: highest iOP eye measurements.
Abbreviation: iOP, intraocular pressure.
so, we used a computerized bottle holder (Travalert®) that 
reminded patients when to instill their eye-drops, assisted 
with the administration, and recorded dosing times of 
  travoprost (Travatan®) and the travoprost/timolol fixed com-
bination Duotrav®.
A total of 140 patients with POAG or OHT were included 
of which 113 (80.7%) were able to use the device and thereby 
report daily compliance figures over 8 successive weeks. This 
represented a high acceptance rate and a high proportion of 
patients able to monitor treatment daily.
Global treatment compliance during the 8 weeks was 60.0%, 
denoting conversely that 40% of the instillations were missed. 
These proportions agree with published reports of compliance 
from various countries.13,14–18,36,37 However, our number (n = 27) 
of low compliance patients is not big enough to give precise 
estimates on non compliance at a population level.
The fact that compliance improved during the first 
week indicates a possible learning effect with Travalert® 
use. No major differences were found between weekdays 
and   weekends, except with low compliance patients during 
the first 4 weeks. The latter would suggest that compliance 
  questions might well focus on weekends when poor IOP 
control is observed in early weeks of treatment.
As Travalert® provided an objective measurement of 
compliance, we did not need to rely on patients’ or oph-
thalmologists’ declarations. It is important to note here that 
although patients agreed to participate in the study and were 
aware that Travalert® recorded their instillations, some still 
did not take their medication. This could be because they 
disliked the device and so stopped using it. Unfortunately, 
patients’ satisfaction with Travalert® was not recorded. The 
reliability of the Travalert® has also been questioned:20,21 eye Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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drops were reliably recorded by the device only after each 
full lever depression. Also, in case of more than 1 iterative 
depression, we counted only on instillation. Lastly, it is 
  possible that the patient is squeezing the container and   placing 
a drop into the sink or manipulating the monitoring device 
by pressing the lever even though they are not trying to place 
a drop in their eye. These are some limitations in terms of 
compliance measurements, since Travalert® cannot actually 
record the eye drop going onto the surface of the eye.
Clusters of patients’ compliance rates were identified 
by a PCA and further analyzed by an AHC. This objective 
approach did not depend on any a priori knowledge of 
what a compliance rate should be to control glaucoma 
progression. Hence, we created homogenous groups of 
compliance profiles and were able to extract relevant 
information (PCA) and minimize intra-group variance 
(AHC). The reliability of our classification was tested 
against measured IOP values. With this approach we 
identified 56.6% of patients showing high compliance and 
22.1% low compliance.
This approach is different from other analyses where 
attempts were made to link last intake time with IOP control, 
the day of the visit. We were not able to identify a cluster of 
patients who took their instillation the days before the visit in 
the purpose to please their doctor, maybe because the size of 
this cluster was too small to be identified. Our poor compliant 
cluster patients were constantly missing their instillations; 
their lack of IOP control occurred every day and is therefore 
likely to be associated with disease progression.
Our 3 compliance groups were comparable on socio-
demographic, eye and general co-morbidities, and glau-
coma parameters. This suggests that compliance prediction 
might involve factors not considered as strictly medical.   
For example, Pappa et al38 recently reported that an 
  immature, defensive personality style increased the risk for 
non-  compliance with glaucoma treatments. We shall deal 
further with this matter in a later paper reporting our Eye-
Drop Satisfaction Questionnaire results. Other factors such 
as disease knowledge, patient-to-clinician relationship, and 
treatment characteristics39,40 would be worth being explored 
when IOP is not controlled.
After 8 weeks of using Travalert®, IOP values decreased 
in all 3 compliance groups (low compliance: –2.28 mmHg; 
medium: –3.04 mmHg; high: –2.92 mmHg). The better 
IOP control after 8 weeks of Travalert® might be explained 
by either an observational bias or the instillation reminder 
of the medical device. It is also important to note that the 
gain in IOP after 8 weeks of Travalert® was lower in the low 
compliance group. However, the mean IOP of medium and 
high compliance groups was lower (–2.0 mmHg, P = 0.02) 
at the last visit than for low compliance patients. The dif-
ference was clinically relevant and supported the findings 
of   Konstas et al.26 Nonetheless, it should be noted that all 
patients who used Travalert®, even those with low compliance, 
achieved an average IOP of 17 mmHg.
Lastly, though the difference did not reach statistical 
significance, IOP values of the low compliance group were 
higher at diagnosis than the values of other patients. This 
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Figure 5 Practitioner evaluations relative to patient compliance groups. P-value: comparison between compliance groups.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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would support a behavioral explanation for poor compliance, 
eg, low compliance patients might possibly be invested less 
in healthcare and delayed their POAG/OHT diagnosis. This 
hypothesis is supported by the absence of correlation between 
IOP at diagnosis and IOP at the last visit, suggesting that our 
results are not confounded by glaucoma severity.
Practitioners rated global Travalert® satisfaction high. All 
individual dimensions rated above the midscale point (3.5). 
When collecting data, practitioners did not know the patients’ 
compliance groups, hence it is interesting that they rated sat-
isfaction on 2 dimensions (‘instillation listing’ and ‘clinical 
interpretation’) similarly for the low and high compliance 
groups. This suggests that information collected by Travalert® 
was relevant to its IOP lowering effect.
Our study has several limitations. First, our sample was 
not recruited randomly and we applied inclusion and exclu-
sion criteria, so extrapolation of compliance prevalence 
rates to the wider glaucoma population in France would be 
questionable. Second, consenting patients knew that their 
compliance could be evaluated, even though Travalert® was 
presented as an instrument to remind and help them instill 
eye-drops. Compliance records might have changed patient 
behavior resulting into overestimated compliance estimates. 
Third, our follow-up period was limited to 8 weeks, which 
was short for a life-long treatment. Fourth, we measured 
IOP only, omitting MD (mean deviation) and PSD (pattern 
standard deviation). Fifth, our patient sample was not large 
enough to identify more than 3 groups of compliance reliably, 
thus necessitating an average IOP difference .2 mmHg for 
statistical significance. Hence, our results need confirmation 
in a larger sample. Also, we were unable to address the effects 
of compliance on visual impairment. Sixth, about one quarter 
of the patients had an additional glaucoma treatment beside 
travaprost or DuoTrav and the compliance of the former was 
not followed up by Travalert. Seventh, our experimental 
design does not allow us to state that Travalert® is a device 
that has a utility at lowering IOP. A randomized clinical 
trial against a control group with several IOP measurements 
should be conducted to confirm this hypothesis.
Conclusions
Most patients were able to record their compliance accu-
rately with Travalert®. The present survey illustrates that 
adherence to IOP-lowering treatment remains a problem. 
Poor compliance was associated with decreased IOP control. 
Lastly, factors predicting compliance were unrelated to socio-
demographic and glaucoma parameters.
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